28
Thu, Mar
51 New Articles

The Upcoming Amendment to the Act on Pharmaceuticals: Will it Mark the end of Drug Shortages?

The Upcoming Amendment to the Act on Pharmaceuticals: Will it Mark the end of Drug Shortages?

Czech Republic
Tools
Typography
  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

For the last couple of months, we have all experienced a shortage of certain pharmaceuticals on the market, especially antibiotics or pharmaceuticals for fever reduction for children. Given that this situation reoccurs almost every flu season, the Ministry of Health of the Czech Republic has newly established a formal working group monitoring the availability of pharmaceuticals on the market. The Ministry of Health is also preparing the amendment to the Act on Pharmaceuticals so that it can, on its own or in cooperation with the State Institute for Drug Control („SUKL“), better respond to urgent drug shortages in case of crisis situations.

In principle, the amendment should introduce rules to better monitor the current amount of pharmaceuticals available on the Czech market, i.e. at pharmacies or held by distributors. Marketing authorisation holders will be required to inform the SUKL of the reasons for the shortage and the corrective measures being taken, together with information on the current stocks of the product. In addition, marketing authorisation holders will also have to ensure the supply of the product for two months after the date of interruption or termination of supply.

Doubtless this measure will help to bridge a short-term lack of pharmaceuticals. But what measure would help bring an end to systematic and long-term drug shortages? The legislation in Poland can partly serve as inspiration. A few years ago, Polish lawmakers introduced the institute of the Chief Pharmaceutical Inspector (“GIF”). Any distributor is in principle obliged to notify its intention to distribute pharmaceuticals listed by the Polish Ministry of Health to a foreign entity. The GIF is entitled to raise an objection against this notification within seven days after receiving it, especially if there is a risk that the pharmaceutical would no longer be available on the domestic market. If no objection is raised within 30 days, the pharmaceutical may be exported.

We can therefore see possible inspiration from the Polish legislation in the list of drugs prohibited for export in the Czech Republic. Nevertheless, while in the Czech Republic this tool was used only in a small number of cases, in Poland the GIF prohibited export in almost 1,000 cases in the first month of its activity alone.

Indeed, this solution comes with many other legal issues as well, such as the elimination of parallel trade of pharmaceuticals or the question of free movement of goods in general. But if we face an exceptional situation with an urgent shortage of critical drugs, this model might at least be worth considering.

By Vladena Svobodova, Associate, JSK, PONTES

 

Czech Republic Knowledge Partner

PRK Partners, one of the leading Central European law firms, has been helping clients achieve their business objectives almost 30 years. Our team of lawyers, based in our Prague, Ostrava, and Bratislava offices, has a unique knowledge of Czech and Slovak law and of the business environment. Our lawyers studied at top law schools in the United States, United Kingdom, Switzerland and elsewhere. They also have experience working for leading international and domestic law firms in a number of jurisdictions. We speak your language, too. Our legal team is fluent in more than 15 languages, including all the key languages of the region.

PRK Partners has one of the most experienced legal teams on the market. We are consistently rated as one of the leading law firms in the region. We have received many significant honours and awards for our work. We represent the interests of international clients operating in the Czech Republic in an efficient way, combining local knowledge with an understanding of their global requirements in a business-friendly approach. We are one of the largest law firms in the Czech Republic and Slovakia. Our specialised teams of lawyers and tax advisors advise major global corporations as well as local companies. We provide comprehensive legal advice drawing on our profound knowledge of local law and markets.

Our legal advice delivers tangible results – as proven by our strong track record. We are the only Czech member firm of Lex Mundi, the world's leading network of independent law firms. As one of the leading law firms in the region, we have received many national and international awards, in some cases several years in a row. Honours include the Chambers Europe Award for Excellence, The Lawyer and Czech and Slovak Law Firm of the Year. Thanks to our close cooperation with leading international law firms and strong local players, we can serve clients in multiple jurisdictions around the globe. Our strong network means that we can meet your needs, wherever you do business.

PRK Partners has been repeatedly voted among the most socially responsible firms in the category of small and mid-sized firms and was awarded the bronze certificate at the annual TOP Responsible Firm of the Year Awards.

Our work is not only “business”: we have participated on a longstanding basis in a wide variety of pro bono projects and supported our partners from the non-profit sector (Kaplicky Centre Endowment Fund, Tereza Maxová Foundation, Czech Donors Forum, etc.).

Firm's website: www.prkpartners.com

Our Latest Issue